GID BIO Blog
Read Updates from GID BIO.
Precision medicine — commonly referred to as personalized medicine — is widely recognized as the future of U.S. healthcare.
Trial measures safety and efficacy of device and point-of-care therapy; first to meet endpoints for reducing pain and improving function
Device and point-of-care therapy intended to treat pain and function could soon help knee osteoarthritis patients
About 30 million U.S. adults suffer from osteoarthritis (OA). Many of these patients put up with pain in the hopes of
FDA-approved trial for cellular implant therapy could mean a major development in the treatment of pain associated with knee osteoarthritis
A randomized controlled Phase IIb clinical trial approved by the Food and Drug Administration (FDA) measuring safety and efficacy of our single-use SVF-2 device
GID BIO aims to close a healthcare gap with the launch of a cost-effective treatment for those suffering from osteoarthritis
Osteoarthritis (OA) is the most common form of arthritis due to the increasing number of U.S. adults 65 and older
GID BIO’s results in randomized controlled Phase IIb clinical study support an evidence-based, data-driven approach to treat pain-management caused by osteoarthritis of the knee
While minimally invasive treatments transformed cardiology decades ago, advancements in orthopedic medicine are introducing potential alternatives to traditional surgery by
GID BIO, a cellular therapy company, moves a step closer to potentially helping relieve the $200 billion osteoarthritis burden on the U.S. healthcare system
AMA grants two Category III CPT® codes, paving the way for reimbursement strategies GID BIO’s unique autologous cellular implant